Lack of Association between miR-605 rs2043556 Polymorphism and Overall Cancer Risk: A Meta-analysis of Case-control Studies

Author(s): Abdolkarim Moazeni-Roodi, Saeid Ghavami, Mohammad Hashemi*.

Journal Name: MicroRNA

Volume 8 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Growing evidence propose an association between miRNA polymorphisms and cancer susceptibility. This study aimed to examine the impact of miR-605 rs2043556 polymorphism on cancer risk through a meta-analysis based on 3198 cancer cases and 4943 controls. Eligible studies were retrieved by searching Web of Science, PubMed, Scopus, and Google Scholar databases up to August 27, 2018. The pooled Odds Ratios (ORs) with 95% Confidence Intervals (CIs) were calculated using a random-effect model to estimate the strength of association between rs2043556 variant of miR-605 and cancer risk. Overall, no significant association was found between miR-605 rs2043556 polymorphism and cancer risk in heterozygous codominant (OR=0.93, 95% CI=0.76-1.13, p=0.44, AG vs. AA), homozygous codominant (OR=1.01, 95%CI=0.78-1.30, p=0.94, GG vs. AA), dominant (OR=0.95, 95% CI=0.79-1.13, p=0.55, AG+GG vs. AA), recessive (OR=1.07, 95%CI=0.84-1.38, p=0.57, GG vs. AG+AA), overdominant (OR=0.93, 95% CI=0.76-1.12, p=0.43, AG vs. GG+AA), and allele (OR=0.98, 95% CI=0.87-1.10, p=0.73, G vs. A) genetic models tested. Stratified analysis by cancer type revealed that the rs2043556 variant was not associated with digestive tract cancer, breast cancer, gastric cancer as well as lung cancer.

Taken together, the findings of this meta-analysis did not support an association between miR-605 rs2043556 polymorphism and cancer susceptibility.

Keywords: Cancer, meta-analysis, miR-605, polymorphism, rs2043556, intron.

[1]
C, Fitzmaurice C, Dicker D, Pain A, et al. Global Burden of Disease Cancer. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27.
[2]
Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
[3]
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
[4]
Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
[5]
Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin 2014; 64: 311-36.
[6]
Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402.
[7]
Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
[8]
Zhang Y, Yun Z, Gong L, et al. Comparison of miRNA evolution and function in plants and animals. MicroRNA 2018; 7(1): 4-10.
[9]
Moazeni-Roodi A, Hashemi M. Association between miR-124-1 rs531564 polymorphism and risk of cancer: an updated meta-analysis of case-control studies. EXCLI J 2018; 17: 608-19.
[10]
Moazeni-Roodi A, Bahari G, Taheri M, Ansari H, Hashemi M. Association between miR-218 rs11134527 polymorphism and risk of selected types of cancer in Asian population: an updated meta-analysis of case-control studies. Gene 2018; 678: 370-6.
[11]
Wang Z, Ji G, Wu Q, et al. Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting FOXO1. Life Sci 2018; 210: 263-70.
[12]
Chen L, Cao Y, Rong D, Wang Y, Cao Y. MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma. Oncol Rep 2017; 38: 1276-86.
[13]
Zhou YJ, Yang HQ, Xia W, et al. Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci 2017; 190: 7-14.
[14]
Xiao J, Lin H, Luo X, Luo X, Wang Z. miR-605 joins p53 network to form a p53: miR-605: Mdm2 positive feedback loop in response to stress. EMBO J 2011; 30: 524-32.
[15]
Morales S, De Mayo T, Gulppi FA, et al. Genetic variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 are associated with breast cancer susceptibility in a south american population. Genes (Basel) 2018; 9(9): E427.
[16]
Xu X, Yin ZH, Ren YW, Guan P, Zhou BS. Associations of miR-605 rs2043556 polymorphism with the susceptibility and overall survival of lung cancer in Chinese non-smoking females. Int J Clin Exp Pathol 2018; 11: 438-47.
[17]
Danesh H, Hashemi M, Bizhani F, Hashemi SM, Bahari G. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene 2018; 647: 73-8.
[18]
Yin Z, Li H, Cui Z, et al. Polymorphisms in pre-miRNA genes and cooking oil fume exposure as well as their interaction on the risk of lung cancer in a Chinese nonsmoking female population. OncoTargets Ther 2016; 9: 395-401.
[19]
Miao L, Wang L, Zhu L, et al. Association of microRNA polymorphisms with the risk of head and neck squamous cell carcinoma in a Chinese population: a case-control study. Chin J Cancer 2016; 35: 77.
[20]
Zhang MW, Jin MJ, Yu YX, et al. Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog 2012; 51(Suppl. 1): E21-31.
[21]
Zhang M, Jin M, Yu Y, et al. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care 2012; 21: 274-80.
[22]
Poltronieri-Oliveira AB, Madeira FF, Nunes DBSM, et al. Polymorphisms of miR-196a2 (rs11614913) and miR-605 (rs2043556) confer susceptibility to gastric cancer. Gene Rep 2017; 7: 154-63.
[23]
Ma F, Zhang P, Lin D, et al. There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. PLoS One 2013; 8: e60195.
[24]
Georges M, Coppieters W, Charlier C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr Opin Genet Dev 2007; 17: 166-76.
[25]
Li J, Tian F, Li D, et al. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett 2014; 588: 3491-500.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2019
Page: [94 - 100]
Pages: 7
DOI: 10.2174/2211536608666181204110508
Price: $58

Article Metrics

PDF: 60
HTML: 3